SCHEMBL4609351

SCHEMBL4609351

Cc1cc(OC(F)(F)F)ccc1N1CCN(S(=O)(=O)CC(Cc2ccccc2)C(=O)NO)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.41
ADAM17 P78536 3/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
ADAM10 O14672 1/20 0.41
MMP14 P50281 1/20 0.41
CHRM4 P08173 2/20 0.39
CHRM2 P08172 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
MMP3 P08254 1/20 0.37
RORC P51449 1/20 0.37
MMP1 P03956 1/20 0.36
MMP13 P45452 1/20 0.36
POLB P06746 1/20 0.36
P2RX7 Q99572 1/20 0.35
TSHR P16473 1/20 0.35
MAPK10 P53779 1/20 0.35
FPR2 P25090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4612774 0.88 LMNA (0.46) CTSSADAM17MMP2MMP9ADAM10
SCHEMBL4609666 0.84 CTSS (0.49) CTSSADAM10POLBTSHRMAPK10
SCHEMBL4610286 0.83 POLB (0.38) ADAM17MMP2MMP9ADAM10MMP14
SCHEMBL4609998 0.78 GRM5 (0.47) CTSSRORC
SCHEMBL4611356 0.78 HSD17B10 (0.54) CTSSPOLB
SCHEMBL6033454 0.77 MMP2 (0.43) MMP2MMP3MMP1POLBEPHX2
SCHEMBL4611829 0.77 GAA (0.50) POLBTSHR
SCHEMBL5669557 0.71 ADAM10 (0.44) CTSSMMP2ADAM10MMP3MMP1
SCHEMBL4610549 0.70 LMNA (0.49) MMP2MMP13POLB
SCHEMBL7156295 0.69 HSD17B10 (0.50) CTSSTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641771-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS UCB PHARMA SA (BE) 2008-10-15 EP claimed
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-10-26 US claimed
EP-1641771-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS UCB PHARMA SA (BE) 2008-10-15 EP disclosed
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD22, CD2, DPP3 CTSS 81/4885ADAM17 57/4885MMP2 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.